<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758104</url>
  </required_header>
  <id_info>
    <org_study_id>1026510</org_study_id>
    <nct_id>NCT04758104</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy of Stereotactic Intracavitary Instillation of 90Yttrium Colloid</brief_title>
  <official_title>Assessment of the Efficacy of Stereotactic Intracavitary Instillation of 90Yttrium Colloid for Treatment of Cystic Lesions of the Brain: Open Label Individual Patient (OLIP) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Clarke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroepithelial cysts are rare, representing less than 1% of the intracranial cysts.&#xD;
      Neuroepithelial cysts, are benign and mostly asymptomatic. These cysts are lined by thin&#xD;
      columnar or low cuboidal epithelium. The CSF-like contents of the cyst are due to secretion&#xD;
      of the epithelial cyst wall. Although mostly asymptomatic, symptoms can occur when the cyst&#xD;
      enlarges; the specific symptoms vary according to the size (mass effect) and location of the&#xD;
      lesion. Radioactive phosphorus (32P) and 90yttrium colloid are isotopes that have been used.&#xD;
      These are approved in the United States and Europe. 32P is not available in Canada. We want&#xD;
      to use 90yttrium colloid. There is evidence in the scientific literature that treatment with&#xD;
      90yttrium colloid injected into the cyst is effective in preventing the cyst from growing,&#xD;
      effective in causing the cyst to get smaller and in some cases the cyst disappears.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In brief, a single patient has been identified as having a cystic tumor by diagnostic imaging&#xD;
      and clinical expertise and based on standards of excellence in clinical care will be offered&#xD;
      participation in the study for the intracystic implantation of 90yttrium colloid. This&#xD;
      patient will be followed closely for 4 weeks following 90yttrium colloid treatment and then&#xD;
      receive standard of care (http://neurosurgery.medicine.dal.ca).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>To estimate the efficacy of intracavitary application of 90Yttrium colloid for the treatment of an adult with a cystic tumor in the brain by a single neurosurgeon.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration of intracavitary application of 90Yttrium colloid into a cystic tumor in the brain.</measure>
    <time_frame>1 MONTH</time_frame>
    <description>90Yttrium colloid will be inserted into the cyst using neurosurgical techniques.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shrinkage of cyst</measure>
    <time_frame>1 Month</time_frame>
    <description>Intracystic application of 90Yttrium colloid will result in the shrinkage of the cyst.To estimate the efficacy of intracavitary application of 90Yttrium colloid for the treatment of an adult with a cystic tumor in the brain by a single neurosurgeon.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PET-CT scan will be used to visualize the yttrium within the cyst.</measure>
    <time_frame>1 -4 days</time_frame>
    <description>We will be evaluating the utility of positron emission tomography - computed tomography (PET-CT) in demonstrating that the distribution of 90yttrium colloid is confined to the cyst.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Neuroepithelial Cyst</condition>
  <arm_group>
    <arm_group_label>Yttrium90</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracystic application of yttrium90</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium90</intervention_name>
    <description>Intracystic implantation of 90yttrium colloid</description>
    <arm_group_label>Yttrium90</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Cystic tumor&#xD;
&#xD;
          2. Required treatment&#xD;
&#xD;
          3. Adult over 17 years of age&#xD;
&#xD;
          4. Willingness to provide informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Solid tumor&#xD;
&#xD;
          2. Treatment not required&#xD;
&#xD;
          3. Child under 17 years of age&#xD;
&#xD;
          4. Not willing to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>David Clarke</investigator_full_name>
    <investigator_title>Neurosurgeon</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

